Vir Biotechnology
VIR | NASDAQ
$9.58
-$0.38 (-3.82%)
At close: Nov 16, 2026, 4:00 PM ET
$9.59
+$0.01 (+0.10%)
After-hours:
Nov 16, 2026, 7:55 PM ET
Vir Biotechnology Company Profile
Company profile explainedCompany Profile
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Marianne De Backer | President, CEO & Director |
| Aziz Sawaf | Executive VP, CFO & Principal Financial Officer |
| Brent Sabatini | Senior Vice President, Principal Accounting Officer & Chief Accounting Officer |
| Carolyn Wang | Senior Vice President of Corporate Communications |
| Jeff Calcagno | Executive Vice President & Chief Business Officer |
| Jennifer Eileen Towne | Executive Vice President & Chief Scientific Officer |
| Kiki Patel | Head of Investor Relations |
| Lawrence Corey | Co-Founder & Scientific Advisor |
| Louis J. Picker | Co-Founder & Scientific Advisor |
| Maninder Hora | Executive Vice President & Chief Technical Operations Officer |
| Toby Medaris | Executive Vice President & Chief Human Resources Officer |
| Vanina De Verneuil | Executive Vice President, General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 4 | Filing |
| Oct 28, 2026 | 3 | Filing |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 08, 2026 | 8-K | Current Report |
| Oct 06, 2026 | 3 | Filing |
| Oct 01, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 4 | Filing |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Vir Biotechnology
| Country | United States |
| IPO Date | Oct 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 367 |
| CEO | Marianne De Backer |
Contact Details
499 Illinois Street San Francisco,
California 94158 United States
Stock Details
| Ticker Symbol | VIR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001706431 |
| CUSIP Number | 92764N102 |
| ISIN Number | US92764N1028 |
| SIC Code | 2836 |
Recent News
- 4 days ago / businesswire.comVir Biotechnology Announces Pricing of Public Offering of Common Stock
- 4 days ago / businesswire.comVir Biotechnology Announces Proposed Public Offering
- 6 days ago / marketbeat.comVir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
- 6 days ago / seekingalpha.comVir Biotechnology: Fairly Valued After Phase 3 Success?
- 8 days ago / seekingalpha.comVir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript
- 8 days ago / investors.comVir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment
- 8 days ago / zacks.comWall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know
- 8 days ago / gurufocus.comVir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
- 8 days ago / gurufocus.comVir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
- 12 days ago / marketbeat.comWhat Vir Biotechnology (VIR) Said on Its Q3 Earnings Call
Add to Watchlist
Select watchlists to add or remove VIR